Victoria M. Pratt, Ph.D., FACMG
Associate Professor of Clinical Medical and Molecular Genetics
Director, Pharmacogenomics Diagnostic Laboratory
- Diplôme de Relations Internationales (B. A. equivalent), 1987, Université Louis Pasteur, Institut Le Bel, Strasbourg, France
- B.S. Biology, 1988, Indiana University, Bloomington IN
- Ph.D. Medical and Molecular Genetics, 1994, Indiana University School of Medicine, Indianapolis IN
- 1994-1996 Postdoctoral Fellowship in Clinical Medical and Clinical Molecular Genetics, Henry Ford Hospital, Detroit MI
Dr. Pratt is a Medical and Clinical Molecular Geneticist board-certified by the American College of Medical Genetics. Prior to joining Indiana University, Dr. Pratt was Chief Director of Molecular Genetics at Quest Diagnostics, Nichols Institute in Chantilly VA.
In addition to her work, Dr. Pratt served on the U.S. Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society for the Oversight of Genetic Testing and the Advisory Committee on Hereditary Disorders in Newborns and Children. She also participated in the preparation of the Morbidity and Mortality Weekly Report for Best Practices in Molecular Genetic Testing for the Centers for Disease Control and Prevention (CDC). Dr. Pratt also served as an advisory member of EurogenTest for genetic test validation.
Dr. Pratt is Past Chair of the Clinical Practice Committee and is currently a member of the Professional Relations committee for the Association of Molecular Pathology. Dr. Pratt serves on the American Medical Association’s (AMA’s) Molecular Pathology Current Procedural Terminology (CPT) Molecular Pathology Advisory committee. . She also continues to serve on the CDC’s GeT-RM program for reference materials for Molecular Genetics. Dr. Pratt is currently serving on Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health.
Dr. Pratt has authored over 40 peer-reviewed manuscripts and book chapters. Additionally, she is the Associate Editor for the Journal of Molecular Pathology.
- Lyon E, Gastier Foster J, Palomaki GE, Pratt VM, Reynolds K, Sábato MF, Vitazka P. Laboratory testing of CYP2D6 alleles for tamoxifen therapy. (2012). Genet Med 2012 14(12):990-1000 (doi: 10.1038/gim.2012.108.)
- Whole Genome Analysis Workgroup (Schrijver I, Aziz N, Farkas DH, Furtado M, Ferreira-Gonzalez A, Grenier TC, Grody WW, Kant JA, Klein RD, Leonard DGB, Lubin IM, Mao R, Nagan N, Pratt VM, Sobel ME, Voelkerding KV, Gibson JS). (2012). Opportunities and Challenges associated with Clinical Diagnostic Genome Sequencing: A White Paper. JMolDiag 14(6):525-540.
- Whole Genome Analysis Workgroup (Gibson J, Aziz N, Bayrak-Toydemir P, Cotter P, Farkas DH, Ferreira-Gonzalez A, Furtado M, Grenier TC, Hambuch T, Klein RD, Leonard DGB, Lyon E, Mann KP, Mao R, Nagan N, Pratt VM, Schrijver I, Sobel ME, Voelkerding KV, William MS). (2011). The Association for Molecular Pathology’s approach to supporting a global agenda to embrace personalized genomic medicine. JMolDiag 13(3):249-251.
- Pratt VM, Zehnbauer B, Amos Wilson J, Baak R, Babic N, Bettinotti M, Buller A, Butz K, Campbell M, Civalier C, El-Badry A, Farkas DH, Lyon E, Mandal S, McKinney J, Muralidharan K, Noll L, Sander T, Shabbeer J, Smith C, Telatar M, Toji L, Vairavan A, Vance C, Weck KE, Wu AHB, Yeo KTJ, Zeller M, Kalman L. (2010). Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1 and UGT1A1: A GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diag. 12(6):835-846.
- Gaedigk A, Jaime LKM, Bertino JS, Bérard A, Pratt VM, Bradford LD, Leeder JS. (2010). Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants. Front Pharmacol 1:1-12 (doi:10.3389/fphar.2010.00121).
- Mattocks CJ, Morris M, Matthijs G, Swinnen E, Corveleyn A, Dequeker E, Müller C, Pratt V, Wallace AJ. (2010). A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 18:1276–1288 (doi:10.1038/ejhg.2010.101).